Associate Director, HEOR/RWE GI

About the role

The Associate Director, HEOR/RWE is an integral part of the organization, responsible for executing HEOR plans and activities related to Revolution Medicines assets intended for use in gastrointestinal cancers. This individual will be responsible for generating evidence that demonstrates the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. This individual will serve as an HEOR expert internally. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology. Reporting to the Executive Director of HEOR/RWE GI, the Associate Director, HEOR/RWE will: Execute the product HEOR/RWE strategy to deliver evidence consistent with the medical strategy and IEP. Deliver HEOR/RWE tactics with quality and in alignment with agreed upon timing. Work with the HEOR/RWE leadership to ensure critical value insights are communicated to key internal teams. Provide HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies. Effectively present research findings to internal stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders. Stay up to date with and add to the advancements in health economics methodologies and best practices; support the build of disease area HEOR/RWE disease area capability, establishing best practices, external visibility, and functional excellence across the medical affairs network. Identify and interface with HEOR & RWE experts and organizations, profile data sources and related organizations as they relate to Revolution Medicines' portfolio and therapeutic areas Closely monitor new trends in health policy and payer environment, assess competitive data gaps and communicate to the organization, to help Revolution Medicines build industry-leading capabilities and be on the cutting edge of evidence-based medicine and HEOR research. Required Skills, Experience and Education: Deep expertise in health economics, outcomes research, patient-reported outcomes or related fields in the biotechnology or pharmaceutical industry. Experience in oncology HEOR and RWE development. Minimum 3 years of relevant experience with an advanced degree in a relevant field (MD, PhD, PharmD). Track record of high impact publications in HEOR/RWE topics. Strong written and interpersonal communication skills, with an ability to present complex technical information clearly. Demonstrated ability to lead evidence generation initiatives and to communicate with impact internally and externally. Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models. Ability to establish relationships with experts in real world evidence (RWE) and therapeutic areas of interest. Preferred Skills: 5+ years of relevant experience in the pharmaceutical/biotech industry. Experience related to gastrointestinal oncology. #LI-Hybrid #LI-VN1 The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities. Revolution Medicines is an eq

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience